Literature DB >> 2452146

A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung.

P Teo1, T H Tai, D Choy, K H Tsui.   

Abstract

Between October 1981 and November 1984, 291 patients with inoperable advanced non-small cell carcinoma of the lung (NSCLC) were randomized to a two-arm study. Eighteen of 291 defaulted treatment and were excluded from the study. Twenty-seven of 273 died during treatment; they were invaluable for treatment response but were included in survival analysis. Without correction for lung attenuation 45 Gy/18 fractions/4 1/2 weeks were given in arm 1 and 31.2 Gy/4 fractions/4 weeks were given in arm 2. One hundred twenty-eight of 273 were included in arm 1 and 145/273 in arm 2. The two arms were comparable in patient age, sex, performance status and symptoms, primary tumor site, histology, stage of the disease, and distribution of metastases and radiation portal size used. Prognosis was poor with an overall median survival of 20 weeks and was similar in both arms. Radiological tumor response was also similar: 53% in arm 1 and 50% in arm 2. However arm 1 was superior than arm 2 in achieving symptom palliation, 71% vs 54%, p less than 0.02. Treatment complications were mild and included mainly radiation oesophagitis and pneumonitis and pulmonary fibrosis. Treatments in both arms were equally well tolerated.

Entities:  

Mesh:

Year:  1988        PMID: 2452146     DOI: 10.1016/0360-3016(88)90007-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

Review 1.  Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer.

Authors:  Rosemary Stevens; Fergus Macbeth; Elizabeth Toy; Bernadette Coles; Jason F Lester
Journal:  Cochrane Database Syst Rev       Date:  2015-01-14

2.  Short term clinical outcomes of accelerated hypofractionated radiotherapy in inoperable non-small cell lung cancer patients.

Authors:  Shoon Mya Aye; Lin Lin Kyi; Moe Hlaing; Aye Aye Myint; Khin Cho Win
Journal:  Rep Pract Oncol Radiother       Date:  2021-09-30

Review 3.  Current landscape of palliative radiotherapy for non-small-cell lung cancer.

Authors:  Raphael Jumeau; Florent Vilotte; André-Dante Durham; Esat-Mahmut Ozsahin
Journal:  Transl Lung Cancer Res       Date:  2019-09

4.  A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC).

Authors:  E Senkus-Konefka; R Dziadziuszko; E Bednaruk-Młyński; A Pliszka; J Kubrak; A Lewandowska; K Małachowski; M Wierzchowski; M Matecka-Nowak; J Jassem
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

5.  Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline.

Authors:  George Rodrigues; Gregory M M Videtic; Ranjan Sur; Andrea Bezjak; Jeffrey Bradley; Carol A Hahn; Corey Langer; Keith L Miller; Benjamin J Moeller; Kenneth Rosenzweig; Benjamin Movsas
Journal:  Pract Radiat Oncol       Date:  2011-04-08

6.  A comparative study of different dose fractionations schedule of thoracic radiotherapy for pain palliation and health-related quality of life in metastatic NSCLC.

Authors:  Sourav Sau; Saikat Sau; Premnath Dutta; Ganesh Chandra Gayen; Sanatan Banerjee; Avijit Basu
Journal:  Lung India       Date:  2014-10

7.  Quality of life measurement in cancer patients receiving palliative radiotherapy for symptomatic lung cancer: a literature review.

Authors:  N Salvo; S Hadi; J Napolskikh; P Goh; E Sinclair; E Chow
Journal:  Curr Oncol       Date:  2009-03       Impact factor: 3.677

8.  Clinical management of pain in advanced lung cancer.

Authors:  Claribel P L Simmons; Nicholas Macleod; Barry J A Laird
Journal:  Clin Med Insights Oncol       Date:  2012-10-08

9.  A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC.

Authors:  M Michael; A Wirth; D L Ball; M MacManus; D Rischin; L Mileshkin; B Solomon; J McKendrick; A D Milner
Journal:  Br J Cancer       Date:  2005-09-19       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.